samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Analytical Service Leaders in Biopharmaceutical and Gene Therapy Development Unify Operations and Re-brand as ProtaGene

Protagen Protein Services



Heilbronn & Heidelberg, Germany and Boston, USA – January 12, 2022: Following the announced merger in July 2021, Protagen Protein Services GmbH, BioAnalytix, Inc, and GeneWerk GmbH today announced their unified operations and re-brand as ProtaGene, a world-leading CRO partner for the biopharmaceutical and cell & gene therapy industries.

The three legacy companies’ combined strength and experience provides the most advanced, integrated, and complete protein and gene analytic service offering for biological therapeutics and cell & gene therapy platforms, all the way from discovery to commercialisation.

Protagen Protein Services, a leading global analytic CRO and expert in protein science, and BioAnalytix, a U.S.-based advanced analytics and data analysis firm, combined in April 2019. GeneWerk, with unique capabilities in vector safety, integration site analysis, and bioinformatics, merged into the group in 2021, creating ProtaGene, a portfolio company of Ampersand Capital Partners.

Martin Blüggel, CEO of ProtaGene and the founder of Protagen Protein Services, said: “We are very excited to launch ProtaGene. The track record and reputation of the three legacy entities are individually impressive, and their combination into a single, globally integrated business delivers significant compounded value for our sponsors. Our new scale and breadth of expertise will benefit the impressive list of innovative products we support, both in development and on the market, and ultimately deliver for patients worldwide. We are passionate in our vision to establish ProtaGene as the world’s leading CRO partner in biologics and cell & gene therapy markets.”

Kirtland Poss, CEO-US of ProtaGene and the founder of BioAnalytix, added, “Our collective expertise and unwavering delivery in both protein and gene analytics are well established. By combining our capabilities, platforms and knowledge, we can now provide our US-based biopharmaceutical and gene therapy customers advanced access to the broadest analytical offering from discovery to market, from a single vendor relationship.”

Annette Deichmann, Senior Vice President of Cell & Gene Therapy at ProtaGene and the cofounder of GeneWerk, said: “We are delighted to embark on this journey, where we will continue to employ our unique expertise and method innovation in cell & gene therapy. Our unique experience in gene analytics – especially integration site analysis, vector purity, vector copy numbers, and bioinformatics analysis for preclinical development and clinical trials – will support many innovators in taking breakthrough therapies to the clinic.”
phone +49 231 9742 61 00
email contact@protagenproteinservices.com
web www.protagenproteinservices.com
email Protagen Protein Services (GmbH), Inselwiesenstraße 10, D-74076 Heilbronn
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Coave Therapeutics to Present Data on its Chemically Engineered AAV Vectors for Gene Therapy in CNS Disease at ASCGT

Paris, France, 4th May 2022 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, today announced that research on its AAV-Ligand Conjugates platform (ALIGATER) will be presented at the 2022 American Society of Cell & Gene Therapy (ASCGT) meeting, which will be held virtually and in person in Washington, D.C., 16 to 19 May.
More info >>


White Papers

PhlexEview: Transforming Costly Paper Processes into Value Driven Compliance

Phlexglobal Ltd

Looking at some of the challenges of traditional paper-based Trial Master Files (TMFs), and how they can be overcome with Phlexglobal's best in breed electronic TMF system, PhlexEview.
More info >>

Industry Events

Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2022)

20-21 June 2022, Berlin, Germany

Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2022) is held on June, 20-21, 2022 in Berlin, Germany. The Congress gathers pharmaceutical companies, CMOs and CDMOs, governmental bodies together with pharmaceutical equipment providers and service companies to discuss the manufacturing and packaging processes of the pharmaceutical industry. Among the participating companies are Bayer, Sandoz, Merck, Novartis, Roche, Genveon, Samsung Biologics, Pfizer.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement